Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that early-onset patients with alopecia universalis or a family history of alopecia areata showed worse prognosis compared to those with late-onset.

In this study, the authors compared topical diphencyprone and tretinoin gel for treating alopecia totalis and universalis, but the abstract does not report any definitive clinical results.

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.

This report describes two patients with alopecia universalis, onychodystrophy, and vitiligo, and found no underlying systemic or etiological causes through extensive investigations.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.

This report describes a case where treatment with the JAK inhibitor ruxolitinib significantly improved beard growth in a patient with severe alopecia areata, emphasizing its potential benefits for populations where beard hair holds cultural significance.

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

In this retrospective study, anti-tuberculous agents, likely rifampicin, were effective adjunctive therapies for a chalazion, coinciding with spontaneous drainage in a patient with rosacea.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

This case report describes a patient with psoriasis and alopecia universalis where psoriasis plaques supported hair growth, suggesting cytokine interaction may influence competing immune responses.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This case study reports that a 23-year-old woman with alopecia universalis experienced complete hair regrowth after six months of treatment with tofacitinib, a JAK-3 inhibitor.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

Upadacitinib effectively treated severe hair loss in a child.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

This report describes the first documented occurrence of Vohwinkel's disease combined with congenital alopecia universalis in siblings from the same family, both unresponsive to prior treatments.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

In this study, 308-nm excimer light therapy showed significant effects in some patients with treatment-resistant alopecia universalis, suggesting it as a potential alternative therapy.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study reports a rare case of a 40-year-old woman with multiple calcified trichilemmal cysts, associated with alopecia universalis and suggesting a potential genetic link.

This case report describes a middle-aged man with alopecia universalis and ulcerative colitis, where hair regrowth occurred following treatment with azathioprine and mesalamine.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

This case report documents a 33-year-old male with autoimmune polyglandular syndrome type 2, including diabetes mellitus type 1, Hashimoto thyroiditis, adrenal insufficiency, and Crohn's disease, highlighting the ongoing difficulties in managing multiple autoimmune conditions.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.